过敏性疾病及其靶向治疗儿童疫苗接种专家共识  

Expert consensus on vaccination of children with allergic diseases and on targeted therapy

作　　者：浙江省预防医学会 中国妇幼保健协会儿童变态反应专业委员会 浙江大学医学院附属儿童医院 郑琪[2] 卢美萍[2] Zhejiang Preventive Medical Association;Pediatric Allergy Committee of China Maternal and Child Health Association;Children's Hospital,Zhejiang University School of Medicine

机构地区：[1]不详 [2]浙江大学医学院附属儿童医院

出　　处：《中国实用儿科杂志》2025年第3期188-193,共6页Chinese Journal of Practical Pediatrics

基　　金：浙江省“尖兵”“领雁”研发攻关计划资助项目(2023C03032)。

摘　　要：儿童过敏性疾病的发病率逐年上升。随着诊疗技术的发展,生物制剂、小分子化合物等靶向药物逐渐应用于过敏性疾病患儿。过敏性疾病患儿由于疾病本身及靶向药物的应用其罹患感染性疾病的风险增加。本共识针对过敏性疾病儿童及其在靶向药物治疗期间疫苗接种相关临床问题进行文献查阅并通过多学科专家讨论,最终形成共识,为儿科临床实践提供参考依据。The incidence of allergic diseases in children is increasing year by year.With the development of diagnosis and treatment technology,targeted therapy such as biologics and small molecule compounds is gradually applied to children with allergic diseases.Children with allergic diseases and those treated with targeted therapy are at increased risk of developing infectious diseases.This consensus reviews the literature on vaccination-related clinical issues of children with allergic diseases and those receiving targeted therapy.Through the multidisciplinary expert discussions,the consensus is finally formed,which is aimed to provide a reference for pediatricians in clinical practice.

关 键 词：靶向治疗 儿童 过敏性疾病 生物制剂 疫苗接种 

分 类 号：R72[医药卫生—儿科]